Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord?
We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the best immunology stocks to invest in. TheFly reported on May 6 that Canaccord initiated coverage on KYMR with a Buy rating and a price target of $106. The firm highlighted the company’s position in developing advanced therapies within the immunology and inflammation field, describing its platform as highly innovative.
Attention was drawn to KT-621, which is currently being evaluated in Phase IIb clinical trials for atopic dermatitis and eosinophilic asthma. The outlook provided includes expectations for regulatory progress, with potential approval in atopic dermatitis projected for 2030 and a later launch in asthma around 2031. Long-term revenue potential was also outlined, with estimates indicating multi-billion-dollar sales opportunities by 2036 across both indications, supported by anticipated commercial expansion and royalty streams.